CureVac

CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.

mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.

CureVac headquartered in Europe, operates in the Biotechnology, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $352.2B in funding across 168 round(s). With a team of 251-500 employees, CureVac is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - CureVac, raised $26.6M. Discover more about their projects, partnerships, and impact on our platform.